^
    Back
    Association details:
    Biomarker:BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H
    Cancer:Ovarian Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Cureus
    Title:

    Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene

    Published date:
    10/11/2021
    Excerpt:
    ...42-year-old Chinese woman with high-grade serous ovarian carcinoma…ovarian tumor showed two BRCA1 pathogenic variants. Germline pathogenic variant of c.2110_2111DelAA and a somatic variant of c.4071_4096+14del40…additional oncogenic mutations; TP53 c.1025G>C p.R342P and NOTCH2 c.3930G> p.Q1310H...A reduced dose of Pemetrexed with Nab-PAClitaxel every three weeks. Immunotherapy with nivolumab every two weeks, and targeted therapy with Temsirolimus, Ramucirumab every three weeks. After the 2nd month of treatment, her performance status was significantly improved from ECOG
    Secondary therapy:
    pemetrexed; paclitaxel
    DOI:
    10.7759/cureus.18691